Ardelyx Shares Rally Premarket on FDA Approval of Xphozah
By Colin Kellaher
Shares of Ardelyx rose sharply in premarket trading Wednesday after the biopharmaceutical company finally won U.S. Food and Drug Administration approval of its Xphozah drug for kidney disease.
After the closing bell on Tuesday, the Waltham, Mass., biopharmaceutical company said the FDA approved Xphozah to reduce serum phosphorus in adults with chronic kidney disease who are on dialysis.
The FDA in 2021 rejected Ardelyx's initial application for approval of Xphozah, but the company appealed, and an FDA advisory committee late last year voted that the drug's benefits outweigh its risks, and the agency in May accepted Ardelyx's resubmitted application for Xphozah.
Ardelyx said the commercial launch for Xphozah is underway, with the drug expected to be available next month.
Ardelyx shares, which closed Tuesday at $3.45, were recently up more than 16% to $4.02 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 18, 2023 08:15 ET (12:15 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
Is the Era of Volatility-Suppressing Policies Possibly Over?
-
5 Undervalued Stocks That Crushed Earnings for Q1 2024
-
What Does Nvidia’s Stock Split Mean for Investors?
-
After Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Baidu Stock a Buy, a Sell, or Fairly Valued?
-
Why Stocks Are Hitting Record Highs—and What Could Send Them Back to Earth
-
2 Wide-Moat Stocks to Consider
-
Live Nation: Breakup Sought by Department of Justice Probably Wouldn’t Affect Fair Value Much
-
After Earnings, Is Applied Materials Stock a Buy, Sell, or Fairly Valued?
-
The Best Energy Stocks to Buy
-
Snowflake Earnings: Mixed News, But Signs of Stability
-
Nvidia Earnings: AI Demand Smashes Expectations Again
-
After Earnings, Is Walmart Stock a Buy, a Sell, or Fairly Valued?
-
Target Earnings: Margins Hold Up, but Top Line Constrained by Weak Discretionary Spending